In this research note, we consider the value and merits of using a pure-play business model (i.e. biotech R&D pipeline, or cash generating services business) against the hybrid approach. Several case studies from the market suggest there may be greater value in focus.
Read the full note here:
This note was written by Raman Minhas and Olivier Koechlin. Raman Minhas is CEO of ATPBio, a strategy and transaction consultancy focused on life sciences. Olivier Koechlin is a Managing Partner at Fraser Finance, a specialist investment bank focused on life sciences and TMT.